Free press releases distribution network?

Agency / Source: Biocompatibles UK Ltd / BTG Plc

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!



CMS Grants New Prospective Reimbursement for Voraxaze - New Technology Add-on Payment provides up to 50% of the cost of Voraxaze® prescribed in the inpatient setting - VoxMedica.com / BTGplc.com
CMS Grants New Prospective Reimbursement for Voraxaze

 

PRZOOM - /newswire/ - West Conshohocken, PA, United States, 2012/09/05 - New Technology Add-on Payment provides up to 50% of the cost of Voraxaze® prescribed in the inpatient setting - VoxMedica.com / BTGplc.com. LSE: BTG

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

BTG International, Inc., the specialist healthcare company, today announces that the Centers for Medicare & Medicaid Services (CMS) has granted a temporary New Technology Add-on Payment (NTAP) for Voraxaze® (glucarpidase), effective 1 October 2012. This new add-on payment means that the US government will pay up to 50% of the cost of Voraxaze® to hospitals in addition to the standard diagnosis-related group (DRG) reimbursement payment. The new add-on payment for Voraxaze® will last 2-3 years until the standard DRGs are recalibrated to include this new technology.

Along with the add-on payment, CMS has also granted Voraxaze® a new ICD-9 procedure code 00.95 (injection or infusion of glucarpidase). Hospitals need to document this new procedure code 00.95 in the first 25 procedure code spaces on the claim form to allow for payment under the NTAP.

NTAP is only available for new technologies which provide a substantial clinical benefit and meet appropriate cost criterion. As it relates to costs, CMS will provide a maximum add-on payment for Voraxaze® of $45,000 per case.

As published in the Federal Register for Medicare inpatient prospective payment system (IPPS) fiscal year 2013, CMS stated,“After reviewing the totality of the evidence and the public comments we received, we agree that Voraxaze® represents a substantial clinical improvement for Medicare beneficiaries.” The IPPS final rule can be found at cms.gov/.

Voraxaze® received US regulatory approval in January 2012 for the treatment of toxic plasma methotrexate concentrations (>1 micromole per liter) in patients with delayed methotrexate clearance due to impaired renal function and is sold in the US by BTG’s dedicated acute care field force. It works by breaking down methotrexate into its inactive metabolites which are then eliminated from the body by routes other than the kidney (primarily the liver).

High dose methotrexate chemotherapy is used to treat or prevent the recurrence of certain types of cancer, such as osteosarcoma, leukemia, and lymphoma. Some patients treated with methotrexate develop impaired kidney function, which leads to the accumulation of toxic levels of methotrexate in the blood and puts patients at risk of additional toxicity.

Matt Gantz, Executive Vice President, US at BTG commented: “Receiving this new inpatient prospective payment highlights the fact that Voraxaze®meets a significant unmet medical need and should help ensure that appropriate patients gain access to it when they need it most. The NTAP will help hospitals cover costs associated with the use of Voraxaze®.”

Indications and Use
Voraxaze® (glucarpidase) is indicated for the treatment of toxic plasma methotrexate concentrations (>1 micromole per liter) in patients with delayed methotrexate clearance due to impaired renal function. Voraxaze® is not indicated for use in patients who exhibit the expected clearance of methotrexate or those with normal or mildly impaired renal function because of the potential risk of subtherapeutic exposure to methotrexate.

Important Safety Information

Adverse Reactions:
• In clinical trials, the common related adverse events (occurring in >1% of patients) were paresthesias, flushing, nausea and/or vomiting, hypotension, and headache.

Warnings and Precautions

Serious Allergic Reactions:
• Serious allergic reactions, including anaphylactic reactions may occur.

Monitoring Methotrexate Concentration/Interference with Assay
• Methotrexate concentrations within 48 hours following Voraxaze® administration can only be reliably measured by a chromatographic method due to interference from metabolites. Measurement of methotrexate concentrations within 48 hours of Voraxaze® administration using immunoassays can overestimate the methotrexate concentration

Continuation and Timing of Leucovorin Rescue
• Leucovorin should not be administered within 2 hours before or afterVoraxaze® dose because leucovorin is a substrate for Voraxaze®.1
• For the first 48 hours after Voraxaze® administer the same leucovorin dose as given prior to Voraxaze®.
• Beyond 48 hours after Voraxaze® administer leucovorin based on the measured methotrexate concentration.
• Do not discontinue therapy with leucovorin based on the determination of a single methotrexate concentration below the leucovorin treatment threshold.
• Therapy with leucovorin should be continued until the methotrexate concentration has been maintained below the leucovorin treatment threshold for a minimum of 3 days.
• Continue hydration and alkalinization of the urine as indicated.

Reference
1. Voraxaze® (glucarpidase) prescribing information January 2012

For further information contact:
Catalina Loveman, Vox Medica
T: +1 215 238 8500 / M: +1 267 746 1627
E: cloveman[.]voxmedica.com.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: Biocompatibles UK Ltd / BTG Plc

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick PRZOOM - Press & Newswire Visibility Checker

 

Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


CMS Grants New Prospective Reimbursement for Voraxaze

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name PRZOOM - Press & Newswire and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
BTG Plc | Vox Medica
Contact: Ashley Tapp - BTGplc.com 
+44(0)20 7575 1513 / +44(0)77 9081 1554 (mobile) ashley.tapp[.]btgplc.com
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Biocompatibles UK Ltd / BTG Plc securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!




Read Latest Press Releases From Biocompatibles UK Ltd / BTG Plc / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Press Releases:

Greenphire Named to Deloitte 2016 Technology Fast 500™
Genentech Showcases New Clinical Data Across a Variety of Blood Diseases at American Society of Hematology 2016 Annual Meeting
BD Collaborates with JDRF to Focus on Extended Wear Innovations for Insulin Infusion Delivery
BD Launches First Syringe Designed for Use with Humulin® R U-500 Insulin
MDxHealth Announces Unique CPT Code Awarded for ConfirmMDx from the American Medical Association
BD MAX™ Vaginal Panel Receives FDA Market Authorization to Detect Most Common Causes of Vaginal Infections
Greenphire Receives EU-US Privacy Shield Certification
The 2016 Georges Mathé Prize Recognizes Research on the Immunological Determinants of the Response to Breast Cancer Treatment
MDxHealth Announces Agreement with HIFU CLINIC Prostate Cancer Center for Distribution of SelectMDx in Poland
First Patient in Malaysia Receives TheraSphere™ Radioembolisation Therapy

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
 
NewswireToday Celebrates 10 Years in Business
Find business coaching, life coaching, executive coaching and corporate coaching, best selling coaching books, ...



PREMIUM Members


Visit  BizJobs.com

Visit  JobsWare.com

Visit  La Bella Bakery Artisan Bakery Arizona







 
  ©2016 PRZOOM — Limelon Advertising, Co.
Home | About PRZOOM | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneur newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today